Hong Kong · Delayed Price · Currency is HKD WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of HKD 230.01 billion. The enterprise value is 225.57 billion.
| Market Cap | 230.01B |
| Enterprise Value | 225.57B |
Important Dates
The next estimated earnings date is Wednesday, November 25, 2026.
| Earnings Date | Nov 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
WuXi Biologics has 4.10 billion shares outstanding. The number of shares has decreased by -0.45% in one year.
| Current Share Class | 4.10B |
| Shares Outstanding | 4.10B |
| Shares Change (YoY) | -0.45% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 39.82% |
| Float | 3.70B |
Valuation Ratios
The trailing PE ratio is 40.99 and the forward PE ratio is 28.18. WuXi Biologics's PEG ratio is 1.34.
| PE Ratio | 40.99 |
| Forward PE | 28.18 |
| PS Ratio | 8.43 |
| PB Ratio | 3.65 |
| P/TBV Ratio | 4.43 |
| P/FCF Ratio | 46.56 |
| P/OCF Ratio | 22.59 |
| PEG Ratio | 1.34 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.28, with an EV/FCF ratio of 45.66.
| EV / Earnings | 39.01 |
| EV / Sales | 8.27 |
| EV / EBITDA | 21.28 |
| EV / EBIT | 25.54 |
| EV / FCF | 45.66 |
Financial Position
The company has a current ratio of 3.32, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.32 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.30 |
| Debt / FCF | 0.64 |
| Interest Coverage | 73.51 |
Financial Efficiency
Return on equity (ROE) is 11.38% and return on invested capital (ROIC) is 13.88%.
| Return on Equity (ROE) | 11.38% |
| Return on Assets (ROA) | 7.60% |
| Return on Invested Capital (ROIC) | 13.88% |
| Return on Capital Employed (ROCE) | 13.38% |
| Weighted Average Cost of Capital (WACC) | 7.61% |
| Revenue Per Employee | 1.85M |
| Profits Per Employee | 393,242 |
| Employee Count | 14,705 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 7.27 |
Taxes
In the past 12 months, WuXi Biologics has paid 1.68 billion in taxes.
| Income Tax | 1.68B |
| Effective Tax Rate | 19.80% |
Stock Price Statistics
The stock price has increased by +41.54% in the last 52 weeks. The beta is 0.62, so WuXi Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +41.54% |
| 50-Day Moving Average | 47.34 |
| 200-Day Moving Average | 38.23 |
| Relative Strength Index (RSI) | 72.62 |
| Average Volume (20 Days) | 28,355,031 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of HKD 27.27 billion and earned 5.78 billion in profits. Earnings per share was 1.37.
| Revenue | 27.27B |
| Gross Profit | 12.95B |
| Operating Income | 8.83B |
| Pretax Income | 8.48B |
| Net Income | 5.78B |
| EBITDA | 10.42B |
| EBIT | 8.83B |
| Earnings Per Share (EPS) | 1.37 |
Balance Sheet
The company has 15.04 billion in cash and 3.15 billion in debt, with a net cash position of 11.89 billion or 2.90 per share.
| Cash & Cash Equivalents | 15.04B |
| Total Debt | 3.15B |
| Net Cash | 11.89B |
| Net Cash Per Share | 2.90 |
| Equity (Book Value) | 62.94B |
| Book Value Per Share | 13.52 |
| Working Capital | 21.94B |
Cash Flow
In the last 12 months, operating cash flow was 10.18 billion and capital expenditures -5.24 billion, giving a free cash flow of 4.94 billion.
| Operating Cash Flow | 10.18B |
| Capital Expenditures | -5.24B |
| Depreciation & Amortization | 1.60B |
| Net Borrowing | -3.04B |
| Free Cash Flow | 4.94B |
| FCF Per Share | 1.20 |
Margins
Gross margin is 47.47%, with operating and profit margins of 32.38% and 21.20%.
| Gross Margin | 47.47% |
| Operating Margin | 32.38% |
| Pretax Margin | 31.10% |
| Profit Margin | 21.20% |
| EBITDA Margin | 38.19% |
| EBIT Margin | 32.38% |
| FCF Margin | 17.87% |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.45% |
| Shareholder Yield | 0.45% |
| Earnings Yield | 2.51% |
| FCF Yield | 2.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for WuXi Biologics is 58.21, which is 3.85% higher than the current price. The consensus rating is "Buy".
| Price Target | 58.21 |
| Price Target Difference | 3.85% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 18.98% |
| EPS Growth Forecast (3Y) | 19.36% |
Stock Splits
The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Nov 16, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
WuXi Biologics has an Altman Z-Score of 8.62 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.62 |
| Piotroski F-Score | 7 |